Accessibility: Skip TopNav

Want to stay updated on the latest news?

Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. CREATE READER ACCOUNT
aavantgarde_logo.jpg
AAVantgarde announces first patient dosed in First-In-Human Phase 1/2 LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related to Usher Syndrome type 1B
September 16, 2024 02:00 ET | AAVantgarde Bio
AAVantgarde announces first patient dosed in First-In-Human Phase 1/2 LUCE-1 study